Form 4: FibroGen CEO Wettig Thane Acquires 145,000 Shares of Common Stock

FibroGen's CEO, Thane Wettig, recently purchased 145,000 shares of the company's common stock at an average price of $0.3494 per share.

Summary

• On March 24, 2025, Thane Wettig, the CEO of FibroGen, Inc. acquired 145,000 shares of common stock.
• The purchase was made at a weighted-average price of $0.3494 per share, with individual prices ranging from $0.34 to $0.37.
• Following the transaction, Wettig directly owns 543,329 shares of FibroGen's common stock.
• Wettig also indirectly owns 1,000 shares through a spouse.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally a good sign, but the document itself is simply a regulatory filing and doesn't contain any explicit sentiment.

Positives

• The CEO's purchase of a significant number of shares could be interpreted as a positive signal about their confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders. This purchase could be seen in the context of overall investor sentiment towards FibroGen and the biotechnology industry.

Comparison to Industry Standards

• Comparing Wettig's stock ownership to CEOs of similar-sized biotech companies could provide context.
• For example, the CEO of a company like Global Blood Therapeutics (GBT) before its acquisition, or a company like Sage Therapeutics, would be a relevant comparison point.
• Analyzing the percentage of company ownership held by the CEO relative to industry averages would be insightful.

Stakeholder Impact

• The CEO's stock purchase could positively influence shareholder confidence.

Key Dates

Keywords

FibroGen, FGEN, Thane Wettig, CEO, stock purchase, Form 4, beneficial ownership, common stock